Beyond Air, Inc. (XAIR) AI Stock Analysis

Beyond Air, Inc. operates at the intersection of medical devices and biopharmaceuticals, focusing on its proprietary LungFit platform. The LungFit platform acts as a generator and delivery system for nitric oxide across various therapeutic settings. The company's flagship product, LungFit PH, is designed to treat persistent pulmonary hypertension of the newborn. Beyond Air is also developing LungFit PRO for treating viral lung infections, including community-acquired viral pneumonia and bronchiolitis in hospitalized patients, and LungFit GO for nontuberculous mycobacteria infections. Headquartered in Garden City, New York, the company was formerly known as AIT Therapeutics, Inc. before rebranding in June 2019.

Beyond Air generated $7.7M in revenue in FY2026, rising 107.3% from $3.7M in FY2025 and up from $59,000 in FY2023. Gross margin turned positive in FY2026 at 3.3%, improving from -44.9% in FY2025 and -112.8% in FY2024. However, the company posted an operating margin of -378.2% and a net income of -$33.2M in FY2026, leading to diluted EPS of -$4.40. Research and development expenses stood at $10.2M in FY2026. For the trailing twelve months ended June 30, 2026, revenue totaled $7.7M with quarterly revenue growth of 0.5% year-over-year, an operating margin of -374.0%, and EPS of -$64.40.

As of June 30, 2026, Beyond Air held $15.2M in cash and short-term investments against total debt of $23.6M, resulting in net debt of $8.4M. Shareholders' equity was $2.0M, contributing to a debt-to-equity ratio of 11.82, while the current ratio stood at 3.31. In FY2026, the company recorded an operating cash flow of -$18.1M and a free cash flow of -$19.2M, alongside capital expenditures of $1.0M. Share count grew 975.0% over the five-year period.

At a share price of $2.16, Beyond Air has a market capitalization of $2.1M and an enterprise value of $16.7M. The stock trades at a price-to-sales ratio of 0.3x, compared to the median of 4.1x for its US-listed Healthcare peers. Its EV-to-revenue multiple is 2.2x, while price-to-book stands at 1.5x. Over the past year, XAIR shares fell 95.6%, while the S&P 500 (SPY) returned 16.8%. Over a five-year period, the stock declined 100.0% compared to an 83.0% gain for the S&P 500.

Wall Street coverage includes 1 Strong Buy and 1 Buy rating. The mean price target is $20.00, representing an 825.9% upside compared to the last close of $2.16. For the current fiscal year ending March 31, 2027, the EPS estimate is -$40.60 with projected revenue of $0. For the next fiscal year, 1 analyst estimates revenue of $21.3M and EPS of -$25.00. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 9, 2026.

This page is an AI-written research summary of Beyond Air, Inc. (XAIR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: XAIR income statement, XAIR balance sheet, XAIR key metrics, XAIR analyst forecast, XAIR chart. See the XAIR stock overview for the latest quote and news.